UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): October 28, 2015
HEARTWARE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-34256 |
|
26-3636023 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
500 Old Connecticut Path
Framingham, MA 01701
(Address of principal executive offices)
Registrants telephone number, including area code:
508.739.0950
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
x |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On October 28, 2015, HeartWare International, Inc. (HeartWare)
distributed a webcast alert attached hereto as Exhibit 99.1 announcing an analyst and investor meeting with the management of HeartWare and Valtech Cardio, Ltd. (Valtech) on November 5, 2015 from 9:00 a.m. to 1:00 p.m.
ET to discuss HeartWares business outlook and provide commentary on HeartWares announced acquisition of Valtech. The webcast can be accessed through HeartWares investor relations website (ir.heartware.com).
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
|
|
|
Exhibit
No. |
|
Description |
|
|
99.1 |
|
Announcement of webcast issued by HeartWare International, Inc. dated October 28, 2015. |
Important Information
As previously disclosed, HeartWare intends to acquire Valtech as set forth in that certain Business Combination Agreement, dated as of September 1, 2015,
by and among HeartWare, Valtech, HW Global, Inc., a Delaware corporation and a direct wholly owned subsidiary of HeartWare (Holdco), HW Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Holdco
(US Merger Sub), Valor Merger Sub Ltd., a private company incorporated under the laws of Israel and a direct wholly owned subsidiary of Holdco (ISR Merger Sub) and Valor Shareholder Representative, LLC, a
Delaware limited liability company, pursuant to which, subject to satisfaction or waiver of the conditions therein, HeartWare and Valtech will effect a strategic combination of their respective businesses under Holdco wherein (a) US Merger Sub
shall merge with and into HeartWare, with HeartWare surviving the merger as a wholly owned subsidiary of Holdco (the US Merger), and (b) ISR Merger Sub shall merge with and into Valtech, with Valtech surviving the merger as a
subsidiary of Holdco (the ISR Merger, together with the US Merger and the other transactions contemplated by the Business Combination Agreement, the Transactions).
Additional Information about the Transactions and Where to Find It
In connection with the proposed Transactions, Holdco has filed a Registration Statement on Form S-4 that contains a preliminary proxy statement/prospectus,
which is not yet final and will be amended. Holdco intends to file a final prospectus and other relevant materials and HeartWare intends to file a definitive proxy statement and other relevant materials with the SEC in connection with the proposed
Transactions. Investors and security holders of HeartWare and Valtech are urged to read these materials when they become available because they will contain important information about HeartWare, Valtech and the Transactions. The proxy
statement/prospectus and other relevant materials (when they become available), and any other documents filed by Holdco or HeartWare with the SEC, may be obtained free of charge at the SEC website at www.sec.gov. In addition, investors and security
holders may obtain free copies of the documents filed with the SEC by Holdco or HeartWare by directing a written request to HeartWares investor relations department at HeartWare International, Inc., 500 Old Connecticut Path, Framingham, MA
01701, Attention: Investor Relations. Investors and security holders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the
Transactions.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any
securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of
securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the Securities Act).
Participants in the Solicitation
HeartWare, Valtech and
their respective directors, executive officers, certain members of management and certain employees may be deemed to be participants in the solicitation of proxies from the stockholders of HeartWare and Valtech in connection with the proposed
transaction. Information regarding the special interests of HeartWares directors and executive officers in the transaction is included in the proxy statement/prospectus referred to above. Additional information regarding the directors and
executive officers of HeartWare is also included in the HeartWare Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the SEC on March 2, 2015. This document is available free of charge at the SEC website
(www.sec.gov) and from Investor Relations at HeartWare at the address described above.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Section 27A of the Securities Act and Section 21E of
the Securities Exchange Act of 1934, as amended. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including, but
not limited to, the ability of the parties to consummate the proposed Transactions; satisfaction of closing conditions to the consummation of the proposed Transactions; the impact of the announcement of the proposed Transactions on HeartWares
relationships with its employees, existing customers or potential future customers; and such other risks and uncertainties pertaining to HeartWares business as detailed in its filings with the SEC on Forms 10-K and 10-Q, which are available on
the SECs website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof. HeartWare assumes no obligation to update any forward-looking statement contained
in this document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
HeartWare International, Inc. |
|
|
|
|
Date: October 28, 2015 |
|
|
|
By: |
|
/s/ Lawrence J. Knopf |
|
|
|
|
Name: |
|
Lawrence J. Knopf |
|
|
|
|
Title: |
|
Senior Vice President, General Counsel and Secretary |
INDEX TO EXHIBITS
|
|
|
Exhibit
No. |
|
Description |
|
|
99.1 |
|
Announcement of webcast issued by HeartWare International, Inc. dated October 28, 2015. |
Exhibit 99.1
HEARTWARE INTERNATIONAL ANALYST AND INVESTOR MEETING
ON NOVEMBER 5, 2015 TO BE WEBCAST
Framingham, Mass., October 28, 2015 - HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory
support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it will be hosting an analyst and investor meeting on November 5, 2015 from 9:00 a.m. ET until 1:00 p.m. ET. The meeting will be webcast
live at http://ir.heartware.com, and a replay will be made available following conclusion of the meeting.
HeartWare senior management will discuss
the companys business outlook and provide commentary on HeartWares announced acquisition of Valtech Cardio, Ltd., a privately held company that specializes in the development of innovative surgical and transcatheter valve repair and
replacement devices for the treatment of mitral and tricuspid valve regurgitation. HeartWares senior management will be joined by Valtechs senior management, as well as a renowned panel of international clinicians with experience in
ventricular assist devices and mitral and tricuspid valve regurgitation interventions, including:
|
|
|
Prof. Karl-Heinz Kuck, M.D., Ph.D. Asklepios Klinik St. Georg, Hamburg, Germany |
|
|
|
Michael Mack, M.D., FACC Baylor Health Care System, Plano, Texas, USA |
|
|
|
Prof. Francesco Maisano, M.D. University Hospital of Zurich, Zurich, Switzerland |
|
|
|
Paul Grayburn, M.D., FACC Baylor University Medical Center, Dallas, Texas, USA |
|
|
|
Paul Jansz, M.D. St. Vincents Hospital, Sydney, Australia |
|
|
|
Steven Boyce, M.D. MedStar Washington Hospital, Washington, D.C., USA |
As part of the meeting,
HeartWare and Valtech will each conduct product demonstrations before and after the presentations.
The live webcast will be accessible on
HeartWares website at http://ir.heartware.com. A replay of the webcast will be available through the same link above following completion of the presentation. A slide presentation to accompany commentary will be made available just
prior to the start of the event in the Investors section of HeartWares website at http://ir.heartware.com.
About Valtech Cardio, Ltd.
Valtech Cardio, Ltd., founded in 2005, is a privately held company specializing in the development of devices for mitral and tricuspid valve repair
and replacement. Valtech has full in-house development, manufacturing, and clinical research capabilities, and over 150 patents and patent applications. The company, comprised of multidisciplinary development teams, works in close collaboration with
world-renowned heart specialists to provide the best possible therapy for mitral patients. Funded in part from investments made by HeartWare International, Inc. (Nasdaq: HTWR) and other private investors, Valtech is headquartered in Or Yehuda,
Israel. For more information, visit the companys website: www.valtechcardio.com.
About HeartWare International
HeartWare International, Inc. develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from
advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small, full-support circulatory assist
device
designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare HVAD System is approved in the United States for the
intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 46 countries. The
device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit www.heartware.com.
Participants in the Solicitation
HeartWare, Valtech and
their respective directors, executive officers, certain members of management and certain employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. A description of the interests in
HeartWare of its directors and executive officers is set forth in HeartWares proxy statement for its 2015 Annual Meeting of Shareholders, which was filed with the Securities and Exchange Commission (the SEC) on April 30, 2015.
This document is available free of charge at the SECs website at www.sec.gov or by going to HeartWares Investors page on its corporate website at www.heartware.com. Additional information regarding the persons who may,
under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, and a description of their direct and indirect interests in the proposed transaction, which may differ from the interests
of HeartWare stockholders or Valtech shareholders generally, was set forth in a preliminary proxy statement/prospectus on file with the SEC.
Additional Information about the Transactions and Where to Find It
In connection with the proposed Transactions, Holdco has filed a Registration Statement on Form S-4 that contains a preliminary proxy statement/prospectus,
which is not yet final and will be amended. Holdco intends to file a final prospectus and other relevant materials and HeartWare intends to file a definitive proxy statement and other relevant materials with the SEC in connection with the proposed
Transactions. Investors and security holders of HeartWare and Valtech are urged to read these materials when they become available because they will contain important information about HeartWare, Valtech and the Transactions. The proxy
statement/prospectus and other relevant materials (when they become available), and any other documents filed by Holdco or HeartWare with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and
security holders may obtain free copies of the documents filed with the SEC by Holdco or HeartWare by directing a written request to HeartWares investor relations department at HeartWare International, Inc., 500 Old Connecticut Path,
Framingham, MA 01701, Attention: Investor Relations. Investors and security holders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with
respect to the Transactions.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an
offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No
offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the Securities Act).
Forward-Looking Statements
This announcement contains
forward-looking statements that are based on managements beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or
anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the: commercialization of HeartWare and Valtech products; timing, progress and outcomes of clinical trials and
regulatory approvals; research and development activities; our ability to integrate, manage and take advantage of acquired and pipeline technology; and the costs and benefits to be achieved from the Valtech transaction. Management believes that
these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. HeartWare does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by federal securities laws and the rules and regulations of the SEC. HeartWare may not actually achieve
the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a
number of risks and uncertainties, including without limitation those described in Part I, Item 1A Risk Factors in HeartWares Annual Report on Form 10-K filed with the SEC. HeartWare may update risk factors from time to time
in Part II, Item 1A Risk Factors in Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the SEC.
HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare logos are trademarks of HeartWare, Inc. or its
affiliates. VALTECH, CARDIOBAND, CARDINAL, CARDIOVALVE, V-CHORDAL and Valtech logos are trademarks of Valtech Cardio, Ltd.
For additional
information:
Christopher Taylor
HeartWare
International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
# # #
Heartware International, Inc. (MM) (NASDAQ:HTWR)
Historical Stock Chart
From Apr 2024 to May 2024
Heartware International, Inc. (MM) (NASDAQ:HTWR)
Historical Stock Chart
From May 2023 to May 2024